COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #249 of 257
2/5 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Fitzgerald et al., medRxiv, doi:10.1101/2021.02.03.21251069 (Preprint)
Risk Factors for Infection and Health Impacts of the COVID-19 Pandemic in People with Autoimmune Diseases
Source   PDF   Share   Tweet
Retrospective 4666 people with autoimmune or inflammatory conditions, showing HCQ adjusted risk of COVID-19 OR 0.91 [0.68-1.23]. Results are not adjusted for the significantly different risk of COVID-19 depending on the type and severity of autoimmune or inflammatory condition.

Fitzgerald et al., 2/5/2021, retrospective, USA, North America, preprint, 34 authors.
risk of COVID-19 case, 8.5% lower, RR 0.91, p = 0.52, treatment 65 of 1072 (6.1%), control 200 of 3594 (5.6%), adjusted per study, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit